Search This Blog

Friday, May 18, 2018

Depression and anxiety strongly linked with autoimmune thyroiditis

There is a strong link between depression and anxiety disorders and autoimmune thyroiditis (AIT), a chronic thyroid condition affecting approximately 10 percent of the population. Scientists at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have now proven that special treatment could help many sufferers, especially women.
Depression and anxiety are among the most common psychiatric disorders across the globe. In 2016 more than 260,000 patients were admitted to hospital for treatment in Germany alone, according to statistics from the Federal Statistics Office.
Together with Prof. Dr. Johannes Kornhuber, Chair of Psychiatry and Psychotherapy at FAU, and scientists from the Psychiatric Clinic at the University of Bonn, Dr. Teja Wolfgang Grömer, medical practitioner in Bamberg and lecturer at the Chair of Psychiatry and Psychotherapy, has now proven a strong link between depression and anxiety disorders and autoimmune thyroiditis. ‘Over the years, I must have been consulted by several hundred people suffering from depression and anxiety,’ reports the psychiatrist and former Max-Planck researcher. ‘At the end of 2015 I noticed a marked connection between AIT and the other two conditions, especially in patients suffering from both. After realising that more than one in two people diagnosed with anxiety and depression – and only in these cases, not other conditions – also tested positive for antibodies I decided to investigate the issue in more detail.’ With the help of the co-authors and a student of psychology at the University of Bamberg, Eva-Maria Siegmann, Dr. Grömer drew up a systematic overview of the current state of research and calculated the strength of the connection on the basis of statistics. For his metastudy, Dr. Grömer combined 21 independent studies based on a total of 36,174 participants. 35,168 of the participants suffered from depression and 34,094 from anxiety.
Initial diagnosis of autoimmune thyroiditis
Dr Grömer stresses that ‘most patients felt a sense of relief after receiving the diagnosis, as very often they had been left with no explanation for their symptoms.’ Autoimmune thyroiditis leads to a lasting inflammation of the thyroid gland. Hormones from the thyroid influence the metabolism and cellular energy balance as well as perceived energy levels and the psyche. AIT leads to specific mental symptoms, including inner unrest, tension and exhaustion. People tend to fall ill between the ages of 30 and 50, with women being affected considerably more often than men. As the disease often first becomes apparent around the same time as the menopause and tends not to cause any pain, it is easy to miss the inflammation of the thyroid gland, or misdiagnose it as ‘menopausal symptoms’ or depression or anxiety alone.
Widespread
The fact is that calculations have shown that patients with AIT are 3.5 times more likely to suffer from depression, or 2.3 times more likely to suffer from anxiety. This doesn’t sound like much at first, but as all three disorders are very common it means that patients with AIT account for more than 40 percent of all cases of depression and 30 percent of all cases of anxiety. Dr. Grömer gives a detailed description of the disease in his article.
The article gives a description based on thorough research of the relevant literature showing how if doctors recognise the links between the disorders they can prescribe a special treatment and use antidepressants that do not affect patients’ weight and the trace element selenium from an early stage. Ensuring that patients are well informed is crucial. Dr. Grömer therefore recommends screening all patients diagnosed with depression and anxiety for AIT, determining which antibodies they have. In addition, in future psychiatric research on depression or anxiety, AIT sufferers should be recognised as a separate group in order to cast more light on the connections.

Opko hit after Novitas issues non-coverage proposal for 4Kscore

Opko Health announced earlier that Novitas Solutions issued a draft local coverage determination for the 4Kscore test. The draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its effectiveness, is subject to a public comment period ending July 5, the company said. OPKO plans to submit comments during this time period. Shares of Opko Health are down 19%, or 94c, to $3.94 in morning trading. The company noted that 4Kscore test has been included in the National Comprehensive Cancer Network Guidelines since 2015, and European Association of Urology Prostate Cancer Guidelines since 2016. Novitas Solutions is an administrative services processing company for government-sponsored health care programs on behalf of the federal government, including the Centers for Medicare and Medicaid Services. Novitas serves as the Medicare Administrative Contractor for a jurisdiction that includes the State of New Jersey, where Opko’s BioReference Laboratories is located and where all 4Kscore test samples are processed.

Medtronic recalls MindFrame Capture LP revascularization device

The FDA announced that Medtronic is recalling the MindFrame Capture LP revascularization device because there is a risk of the delivery wire breaking or separating during use. The clot retriever could be left inside the patient’s bloodstream, and this or the attempts made to retrieve the device, can lead to further complications including bleeding, additional blockage of blood vessels, more severe stroke symptoms, or death. “The FDA has identified this as a Class I recall, the most serious type of recall,” the recall notice states

Rocket Pharma has ‘encouraging’ data from anemia gene therapy trial

Rocket Pharmaceuticals announced the presentation of updated data from the ongoing Phase 1/2 clinical trial of RP-L102, the company’s lead lentiviral vector-based gene therapy, for Fanconi Anemia. The data were highlighted today in an oral presentation during the distinguished Presidential Symposium at the ASGCT 2018 Annual Meeting, by Dr. Juan Bueren, Head of the Hematopoietic Innovative Therapies Division at the Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas in Spain / CIBER-Rare Diseases / IIS-Fundacion Jimenez Diaz, and program principal investigator of the RP-L102 trial. “Several important observations are emerging from our ongoing Phase 1/2 trial in FA. First, even without myeloablative conditioning, there are increasing levels of bone marrow engraftment following administration of RP-L102. Second, the improvement of chromosomal stability in corrected FA cells indicates that RP-L102 is reversing the FA phenotype. Third, the natural progression of bone marrow failure in these patients is reversed. In fact, the bone marrow cells of the two patients who received higher doses demonstrate conversion to a somatic mosaic status that is sustained over the course of several months. Finally, the progressive increases of corrected, versus non-corrected, peripheral blood leukocytes indicate that RP-L102 is restoring functionality of bone marrow hematopoietic stem cells. This translates to a stabilization in peripheral blood cell counts which would otherwise continue to decline in the absence of treatment. Based on these encouraging results, I believe that RP-L102 has the potential to be a transformative and minimally toxic prevention of bone marrow failure for FA,” said Dr. Bueren.

Celgene multiple myeloma event webcast May 24

Research & Development Deep Dive on Multiple Myeloma will be held on May 24 at 1:30 pm
Webcast: https://edge.media-server.com/m6/p/vsoa43es

Parrot Uses Alexa To Run Her Owner’s House

A very chatty parrot has found a new toy that’s allowing her to run an entire house. Using Amazon’s Alexa, Petra the parrot is becoming an Internet sensation after learning to give the voice-activated device commands.
“First, you’re like half awake and … like, ‘Was that a dream? Did that just happen?’” her owner told WKMG. “All day, every day, it’s all lights on, all lights off.”
The tech-savvy African Grey Congo parrot is only four-years-old and reportedly knows more than 300 words, making her conversations with the virtual home assistant an instant social media hit.
Petra’s owner has created a YouTube channel for the clever bird. Over 13,000 people have already subscribed to see Petra’s adventures in her Florida home; many of them featuring her new digital sidekick. She’s even been filmed video chatting with another chatty bird, Einstein the Talking Texan Parrot, during a recent Facebook post.
“We’ve been told she’s the smartest bird in the world!” her owner wrote on Petra’s official Facebook page. The four-year-old is already working on a new trick to entertain her followers. According to Petra’s owner, she’s now learning how to talk to Google Home.

Abeo hit on gene therapy data

Abeona Therapeutics (ABEO -11.5%) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of sugar molecules in tissues and organs leading to a range of health problems.
To date, 11 patients have received a single intravenous injection of ABO-102 which delivers the missing gene associated with the disease.
Reductions in heparan sulfate, the hallmark sugar molecule in MPS III A, in cerebral spinal fluid were 25.8 – 67.1% at day 30 (3 – 4 patients), 58.7 – 83.3% at day 180 (1 -3 patients) and 65.7 – 69.3% at day 360 (2 patients).
In urine, the reductions in heparan sulfate ranged from 29.2 – 90.3% from day 30 to day 540.
Patients experienced durable biophysical reductions of disease burden, including reductions in liver volume.
On the safety front, no treatment-related serious adverse events were observed.
Investors appeared to have sold on the news since shares were initially down almost 26% before recovering.